XML 148 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2020
USD ($)
obligation
bundle
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
$ / shares
Mar. 31, 2023
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Development regulatory and sales milestones payments   $ 2,800,000      
Revenues   $ 3,551 $ 62,546    
Diluted (in dollars per share) | $ / shares   $ (1.24) $ (0.39)    
Accrued expenses   $ 46,604   $ 39,763  
Takeda | License and Co-Funding Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Number of distinct performance obligations | obligation 1        
Number of distinct bundle | bundle 1        
Initial transaction price $ 300,000        
Milestone payment         $ 40,000
Revenues       $ 70,500  
Diluted (in dollars per share) | $ / shares       $ 0.66  
Deferred revenue recognized   900      
Accrued expenses   11,100      
Takeda | License and Co-Funding Agreement | Minimum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Percentage of eligible to receive tiered royalties on net sales 20.00%        
Takeda | License and Co-Funding Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Percentage of eligible to receive tiered royalties on net sales 25.00%        
Development regulatory and sales milestones payments   $ 527,500